Assessing the Efficacy of Cidofovir Against Herpesvirus-induced Genital Lesions in Goats Using Different Therapeutic Regimens

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2008 Sep 4

PMID 18765685

Citations 3

Authors

M Tempesta

G Crescenzo

M Camero

A L Bellacicco

E Tarsitano

N Decaro

J Neyts

V Martella

C Buonavoglia

Affiliations

Soon will be listed here.

Abstract

Caprine herpesvirus 1 (CpHV-1) infection in goats induces genital vesicular-ulcerative lesions that strictly resemble those produced by human herpesvirus 2 in humans. In previous studies, the potent inhibition of CpHV-1 by cidofovir was demonstrated. Cidofovir antiherpetic activity was evaluated in goats infected experimentally by the vaginal route with CpHV-1 and then treated locally at different times after infection. The administration of 1% cidofovir cream onto vaginal mucosa was able to prevent the onset of genital lesions and to decrease significantly the titers of the virus shed by the infected animals, notably in the groups treated shortly after infection (24 and 48 h). The efficacy of cidofovir against caprine herpesvirus infection was higher when the treatment was started shortly after infection than when lesions were already present and advanced. Herpesvirus genital infection of goats is a useful animal model to study the activity of antiviral drugs against human herpesvirus infections.

Citing Articles

A Simple and Versatile Method for Ex Vivo Monitoring of Goat Vaginal Mucosa Transduction by Viral Vector Vaccines.

Minesso S, Odigie A, Franceschi V, Cotti C, Cavirani S, Tempesta M Vaccines (Basel). 2024; 12(8).

PMID: 39203977 PMC: 11359855. DOI: 10.3390/vaccines12080851.

In Vitro Activity of Ozone/Oxygen Gaseous Mixture against a Caprine Herpesvirus Type 1 Strain Isolated from a Goat with Vaginitis.

Lillo E, Pellegrini F, Rizzo A, Lanave G, Zizzadoro C, Cicirelli V Animals (Basel). 2023; 13(12).

PMID: 37370430 PMC: 10295554. DOI: 10.3390/ani13121920.

Clinical protection of goats against CpHV-1 induced genital disease with a BoHV-4-based vector expressing CpHV-1 gD.

Donofrio G, Franceschi V, Lovero A, Capocefalo A, Camero M, Losurdo M PLoS One. 2013; 8(1):e52758.

PMID: 23300989 PMC: 3536792. DOI: 10.1371/journal.pone.0052758.

References

De Clercq E . The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res. 2006; 75(1):1-13. DOI: 10.1016/j.antiviral.2006.10.006. View

Yoshikawa T, Hill J, Stanberry L, Bourne N, Kurawadwala J, Krause P . The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region. J Exp Med. 1996; 184(2):659-64. PMC: 2192722. DOI: 10.1084/jem.184.2.659. View

Tempesta M, Camero M, Bellacicco A, Thiry J, Crescenzo G, Neyts J . Cidofovir is effective against caprine herpesvirus 1 infection in goats. Antiviral Res. 2006; 74(2):138-41. DOI: 10.1016/j.antiviral.2006.11.001. View

Maggs D, Clarke H . In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004; 65(4):399-403. DOI: 10.2460/ajvr.2004.65.399. View

Tempesta M, Pratelli A, Corrente M, Buonavoglia C . A preliminary study on the pathogenicity of a strain of caprine herpesvirus-1. Comp Immunol Microbiol Infect Dis. 1999; 22(2):137-43. DOI: 10.1016/s0147-9571(98)00029-0. View

De Clercq E, Holy A . Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov. 2005; 4(11):928-40. DOI: 10.1038/nrd1877. View

Garre B, Van Der Meulen K, Nugent J, Neyts J, Croubels S, De Backer P . In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet Microbiol. 2007; 122(1-2):43-51. DOI: 10.1016/j.vetmic.2007.01.004. View

Tempesta M, Greco G, Pratelli A, Buonavoglia D, Camero M, Martella V . Reactivation of caprine herpesvirus 1 in experimentally infected goats. Vet Rec. 2002; 150(4):116-7. DOI: 10.1136/vr.150.4.116. View

Stragier I, Snoeck R, De Clercq E, van den Oord J, Van Ranst M, De Greef H . Local treatment of HPV-induced skin lesions by Cidofovir. J Med Virol. 2002; 67(2):241-5. DOI: 10.1002/jmv.2213. View

10.

Zabawski Jr E . A review of topical and intralesional cidofovir. Dermatol Online J. 2001; 6(1):3. View

11.

Gilliam S, FIELD H . The effect of (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC) on bovine herpesvirus-1 (BHV-1) infection and reactivation in cattle. Antiviral Res. 1993; 20(1):21-32. DOI: 10.1016/0166-3542(93)90056-o. View

12.

Tempesta M, Camero M, Bellacicco A, Tarsitano E, Crescenzo G, Thiry J . Potent inhibition of genital herpesvirus infection in goats by cidofovir. Antivir Ther. 2007; 12(6):977-9. View

13.

Tempesta M, Pratelli A, Greco G, Martella V, Buonavoglia C . Detection of caprine herpesvirus 1 in sacral ganglia of latently infected goats by PCR. J Clin Microbiol. 1999; 37(5):1598-9. PMC: 84844. DOI: 10.1128/JCM.37.5.1598-1599.1999. View

14.

De Clercq E . Antiviral drugs in current clinical use. J Clin Virol. 2004; 30(2):115-33. DOI: 10.1016/j.jcv.2004.02.009. View

15.

Scagliarini A, McInnes C, Gallina L, Dal Pozzo F, Scagliarini L, Snoeck R . Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs. Antiviral Res. 2006; 73(3):169-74. PMC: 1930164. DOI: 10.1016/j.antiviral.2006.09.008. View

16.

Buonavoglia C, Tempesta M, Cavalli A, Voigt V, Buonavoglia D, Conserva A . Reactivation of caprine herpesvirus 1 in latently infected goats. Comp Immunol Microbiol Infect Dis. 1996; 19(4):275-81. DOI: 10.1016/0147-9571(96)00014-8. View

17.

Gibson J, Slater J, FIELD H . The activity of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine (HPMPC) against equine herpesvirus-1 (EHV-1) in cell cultures, mice and horses. Antiviral Res. 1992; 19(3):219-32. DOI: 10.1016/0166-3542(92)90081-f. View

18.

Lafferty W, Coombs R, Benedetti J, Critchlow C, Corey L . Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med. 1987; 316(23):1444-9. DOI: 10.1056/NEJM198706043162304. View